DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Peterson Wealth Services

Peterson Wealth Services boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 7.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,030 shares of the medical device company’s stock after acquiring an additional 201 shares during the period. Peterson Wealth Services’ holdings in DexCom were worth $236,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Blue Whale Capital LLP lifted its holdings in shares of DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after purchasing an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its stake in DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after buying an additional 11,075 shares during the last quarter. Brooktree Capital Management purchased a new stake in DexCom in the third quarter valued at approximately $683,000. National Pension Service boosted its holdings in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after acquiring an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new position in shares of DexCom during the third quarter worth approximately $650,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock worth $3,628,069 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Wells Fargo & Company increased their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Raymond James decreased their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Finally, Royal Bank of Canada dropped their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $98.41.

DexCom Price Performance

DXCM stock opened at $88.27 on Tuesday. The stock’s 50 day moving average price is $81.76 and its 200 day moving average price is $75.11. The firm has a market cap of $34.48 billion, a P/E ratio of 52.86, a PEG ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.